Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0IMQRY)
| ADC Name |
Debio 1562M
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
Debio 1562M
Click to Show/Hide
|
|||||
| Organization |
Debiopharm (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Naratuximab
|
Antibody Info | ||||
| Antigen Name |
Leukocyte antigen CD37 (CD37)
|
Antigen Info | ||||
| Payload Name |
DM1
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
MultilinkTM Cleavable Linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Acute myeloid leukaemia |
1 Trials
|